相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
Joana Torres et al.
JOURNAL OF CROHNS & COLITIS (2020)
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial
A. Blauvelt et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis
Joseph D. Feuerstein et al.
GASTROENTEROLOGY (2020)
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel -group, randomised, active-controlled, phase 3b trial
Iain B. McInnes et al.
LANCET (2020)
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
Laure Gossec et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial
Kristian Reich et al.
LANCET (2019)
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial
Kristian Reich et al.
LANCET (2019)
Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis
Atul Deodhar et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Role of comorbidities in spondyloarthritis including psoriatic arthritis
Silvia Scriffignano et al.
CLINICAL RHEUMATOLOGY (2019)
New onset/recurrence of inflammatory arthralgia/spondyloarthritis in patients treated with vedolizumab for intestinal bowel disease
Silvia Tamanini et al.
CLINICAL RHEUMATOLOGY (2019)
Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab - The GO-EASY Study
Rianne E. van Bentum et al.
JOURNAL OF RHEUMATOLOGY (2019)
Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
Jasvinder A. Singh et al.
ARTHRITIS CARE & RESEARCH (2019)
EFFICACY AND SAFETY OF BRODALUMAB, AN ANTI-INTERLEUKIN-17 RECEPTOR A MONOCLONAL ANTIBODY, IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: A 16 WEEK RESULTS OF A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
James Cheng-Chung Wei et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
A Review of Immune-Mediated Adverse Events in Melanoma
Lucy Boyce Kennedy et al.
ONCOLOGY AND THERAPY (2019)
Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis
C. Ryan et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Arthrits occurrence or reactivation under Vedolizumab treatment for inflammatory bowel disease. A four cases report
Daniel Wendling et al.
JOINT BONE SPINE (2018)
Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2
Brian G. Feagan et al.
JOURNAL OF CROHNS & COLITIS (2018)
Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study
Atul Deodhar et al.
LANCET (2018)
JAK/STAT - Emerging Players in Metabolism
David W. Dodington et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2018)
Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials.
Kim A. Papp et al.
VALUE IN HEALTH (2018)
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
Dominique Baeten et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Abatacept for the treatment of psoriatic arthritis
Ennio Lubrano et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2018)
Golimumab in the treatment of psoriatic arthritis
Thorvardur Jon Love et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2018)
Treatment of psoriatic arthritis with secukinumab: a case series
Stefania Nicola et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2018)
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
Kim Papp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The IL-20 Cytokine Family in Rheumatoid Arthritis and Spondyloarthritis
Tue W. Kragstrup et al.
FRONTIERS IN IMMUNOLOGY (2018)
Bridging the Gaps in the Care of Psoriasis and Psoriatic Arthritis: the Role of Combined Clinics
Rebecca Haberman et al.
CURRENT RHEUMATOLOGY REPORTS (2018)
Association of Psoriasis With Inflammatory Bowel Disease A Systematic Review and Meta-analysis
Yun Fu et al.
JAMA DERMATOLOGY (2018)
An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease: a case series
G. Varkas et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Psoriasis pathogenesis and the development of novel targeted immune therapies
Jason E. Hawkes et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatore-controlled VOYAGE 1 trial
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparatore-controlled VOYAGE 2 trial
Kristian Reich et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
The role of IL-23 and the IL-23/TH17 immune axis in the pathogenesis and treatment of psoriasis
G. Girolomoni et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC
A. Nast et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
Peter Nash et al.
LANCET (2017)
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
Kristian Reich et al.
LANCET (2017)
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
Brian G. Feagan et al.
LANCET (2017)
Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study
K. Reich et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study
Desiree van der Heijde et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
TNF biology, pathogenic mechanisms and emerging therapeutic strategies
George D. Kalliolias et al.
NATURE REVIEWS RHEUMATOLOGY (2016)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease
Stephan R. Targan et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2016)
Nail Psoriasis: A Review of Treatment Options
Marcel C. Pasch
DRUGS (2016)
Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic Arthritis
Philip J. Mease et al.
JOURNAL OF RHEUMATOLOGY (2016)
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
K. B. Gordon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Ankylosing Spondylitis and Axial Spondyloarthritis
Joel D. Taurog et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis
M. Rudwaleit et al.
ARTHRITIS CARE & RESEARCH (2016)
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis
Laura C. Coates et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Uveitis in spondyloarthritis including psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease
James T. Rosenbaum
CLINICAL RHEUMATOLOGY (2015)
Apremilast: A Review in Psoriasis and Psoriatic Arthritis
Emma D. Deeks
DRUGS (2015)
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
Christopher E. M. Griffiths et al.
LANCET (2015)
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
M. Lebwohl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficacy and Safety of Intravenous Secukinumab in Noninfectious Uveitis Requiring Steroid-Sparing Immunosuppressive Therapy
Erik Letko et al.
OPHTHALMOLOGY (2015)
Biologic Therapy for Psoriatic Arthritis
Philip J. Mease
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2015)
Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1
J. Sieper et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn's Disease
William J. Sandborn et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis
Philip J. Mease et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials
Richard G. Langley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis
Ejaz Pathan et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis
J. P. Ortonne et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Secukinumab in the Treatment of Noninfectious Uveitis: Results of Three Randomized, Controlled Clinical Trials
Andrew D. Dick et al.
OPHTHALMOLOGY (2013)
Abatacept for Crohn's Disease and Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2012)
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
Wolfgang Hueber et al.
GUT (2012)
Moderate to severe plaque psoriasis with scalp involvement: A randomized, double-blind, placebo-controlled study of etanercept
Jerry Bagel et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study
I-H Song et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Antibodies Against Tumor Necrosis Factor (TNF) Induce T-Cell Apoptosis in Patients With Inflammatory Bowel Diseases via TNF Receptor 2 and Intestinal CD14+ Macrophages
Raja Atreya et al.
GASTROENTEROLOGY (2011)
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Christopher E. M. Griffiths et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002
Russell Cohen et al.
INFLAMMATORY BOWEL DISEASES (2008)
Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study
S. Guignard et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors
B Bodaghi et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-α
H Mitoma et al.
GASTROENTEROLOGY (2005)
Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease
JMH Van Den Brande et al.
GASTROENTEROLOGY (2003)
Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate
CS Foster et al.
ARCHIVES OF OPHTHALMOLOGY (2003)
Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease
T ten Hove et al.
GUT (2002)
Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
WJ Sandborn et al.
GASTROENTEROLOGY (2001)
分享论文
